160 related articles for article (PubMed ID: 22200915)
1. Distribution of estimated glomerular filtration rate (eGFR) values in patients receiving contrast-enhanced magnetic resonance imaging.
Shimoji K; Aoki S; Nakanishi A; Suzuki M; Hori M; Sato S; Hoshito H; Kyogoku S; Cho N; Ozaki Y; Suzuki M; Kuwatsuru R; Sasai K
Jpn J Radiol; 2012 Feb; 30(2):116-9. PubMed ID: 22200915
[TBL] [Abstract][Full Text] [Related]
2. No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid.
Starekova J; Bruce RJ; Sadowski EA; Reeder SB
Radiology; 2020 Dec; 297(3):556-562. PubMed ID: 32990511
[TBL] [Abstract][Full Text] [Related]
3. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases.
Perez-Rodriguez J; Lai S; Ehst BD; Fine DM; Bluemke DA
Radiology; 2009 Feb; 250(2):371-7. PubMed ID: 19188312
[TBL] [Abstract][Full Text] [Related]
4. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.
Wang Y; Alkasab TK; Narin O; Nazarian RM; Kaewlai R; Kay J; Abujudeh HH
Radiology; 2011 Jul; 260(1):105-11. PubMed ID: 21586680
[TBL] [Abstract][Full Text] [Related]
5. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden.
Alhadad A; Sterner G; Svensson Å; Alhadad H; Leander P
Scand J Urol Nephrol; 2012 Feb; 46(1):48-53. PubMed ID: 22008005
[TBL] [Abstract][Full Text] [Related]
6. Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment.
Gauthier ID; Macleod CA; Sathiadoss P; McGrath TA; Nair V; Schieda N
Abdom Radiol (NY); 2022 Mar; 47(3):1196-1201. PubMed ID: 34997298
[TBL] [Abstract][Full Text] [Related]
7. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
[TBL] [Abstract][Full Text] [Related]
8. Nephrogenic systemic fibrosis: A survey of the use of gadolinium-based contrast agents in Ghana.
Piersson AD; Gorleku PN
Radiography (Lond); 2017 Nov; 23(4):e108-e113. PubMed ID: 28965904
[TBL] [Abstract][Full Text] [Related]
9. A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR.
Lohani S; Golenbiewski J; Swami A; Halalau A
BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 29025775
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases.
Zou Z; Zhang HL; Roditi GH; Leiner T; Kucharczyk W; Prince MR
JACC Cardiovasc Imaging; 2011 Nov; 4(11):1206-16. PubMed ID: 22093272
[TBL] [Abstract][Full Text] [Related]
11. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.
Rudnick MR; Wahba IM; Leonberg-Yoo AK; Miskulin D; Litt HI
Am J Kidney Dis; 2021 Apr; 77(4):517-528. PubMed ID: 32861792
[TBL] [Abstract][Full Text] [Related]
12. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Woolen SA; Shankar PR; Gagnier JJ; MacEachern MP; Singer L; Davenport MS
JAMA Intern Med; 2020 Feb; 180(2):223-230. PubMed ID: 31816007
[TBL] [Abstract][Full Text] [Related]
13. Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment.
Alfano G; Fontana F; Ferrari A; Solazzo A; Perrone R; Giaroni F; Torricelli P; Cappelli G
Magn Reson Imaging; 2020 Jul; 70():1-4. PubMed ID: 32112811
[TBL] [Abstract][Full Text] [Related]
14. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
[TBL] [Abstract][Full Text] [Related]
15. Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.
Becker S; Walter S; Witzke O; Kreuter A; Kribben A; Mitchell A
Nephron Clin Pract; 2012; 121(1-2):c91-4. PubMed ID: 23182840
[TBL] [Abstract][Full Text] [Related]
16. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide.
Bruce R; Wentland AL; Haemel AK; Garrett RW; Sadowski DR; Djamali A; Sadowski EA
Invest Radiol; 2016 Nov; 51(11):701-705. PubMed ID: 26885631
[TBL] [Abstract][Full Text] [Related]
17. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.
Tsushima Y; Kanal E; Thomsen HS
Br J Radiol; 2010 Jul; 83(991):590-5. PubMed ID: 20413447
[TBL] [Abstract][Full Text] [Related]
18. Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals.
Young LK; Matthew SZ; Houston JG
Eur Radiol; 2019 Apr; 29(4):1922-1930. PubMed ID: 30276674
[TBL] [Abstract][Full Text] [Related]
19. Gadolinium-associated nephrogenic systemic fibrosis.
Schlaudecker JD; Bernheisel CR
Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
[TBL] [Abstract][Full Text] [Related]
20. Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration.
Kanal E; Patton TJ; Krefting I; Wang C
AJNR Am J Neuroradiol; 2020 Mar; 41(3):393-399. PubMed ID: 32115422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
